Thu 4/25/2019 19:49 ET
DJIA26462.08134.960.51%TELCO164.260.000.00%GOLD1280.550.900.07%Shanghai3123.8375.912.43%
S&P 5002926.171.170.04%BANKS452.460.000.00%OIL64.970.240.37%BITCOIN5151.29286.415.56%
NASDAQ8118.6817.050.21%PHARM559.600.000.00%US/EU1.110.000.00%Futures2925.121.170.04%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Nabriva Therapeutics AG - NBRV   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  
From: burp (Rep: 73)Date: 12/20/2018 07:38
Forum: Nabriva Therapeutics AG - Msg #97Thread #674053008 (Rec: 0)
Both formulations of lefamulin were granted Qualified Infectious Disease Product and Fast Track designation by the FDA, enabling potential Priority Review of the NDAs by the FDA. Nabriva Therapeutics plans to submit a marketing authorization application for lefamulin in Europe in the first quarter of 2019.

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser burp: Reward | Watch | IgnoreNBRV: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add NBRV
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.